Filing Flows › Comparisons › TSHA vs SRZN
Taysha Gene Therapies vs Surrozen: TSHA and SRZN compared
Taysha Gene Therapies is the larger company: $5.5M of revenue in its latest quarter (Q4 2025) against $5.0M for Surrozen (Q2 2026). Surrozen is growing faster (+409% against +171% a year earlier). Surrozen is more profitable, with an operating margin of -207.4% against -516.0%.
Where the money goes: TSHA and SRZN
Taysha Gene Therapies (TSHA) · Q4 2025
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
Surrozen (SRZN) · Q2 2026
Surrozen, Q2 2026: revenue $5.0M (+409% year over year), operating margin -207.4%, net earnings $50.2M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Taysha Gene Therapies (TSHA) | Surrozen (SRZN) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $5.5M | $5.0M |
| Revenue growth, Y/Y | +171% | +409% |
| Operating margin | -516.0% | -207.4% |
| Net earnings | −$27.9M | $50.2M |
| Net margin | -507.8% | — |
| Operating cash flow | −$26.7M | −$7.4M |
Questions
Which is bigger, Taysha Gene Therapies or Surrozen?
Taysha Gene Therapies is the larger company: $5.5M of revenue in its latest quarter (Q4 2025) against $5.0M for Surrozen (Q2 2026).
Is Taysha Gene Therapies or Surrozen growing faster?
Surrozen is growing faster (+409% against +171% a year earlier).
Which is more profitable, Taysha Gene Therapies or Surrozen?
Surrozen is more profitable, with an operating margin of -207.4% against -516.0%.
More: Taysha Gene Therapies earnings · how Taysha Gene Therapies makes money · Surrozen earnings · how Surrozen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 19, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.